How big is Abacus Life, Inc.?

As of Jun 18, Abacus Life, Inc. has a market capitalization of 536.49 million and reported net sales of 0.00 million with a net profit of -18.24 million. As of Dec 24, shareholder's funds were 424.15 million, and total assets amounted to 884.58 million.

As of Jun 18, Abacus Life, Inc. has a market capitalization of 536.49 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -18.24 million.<BR><BR>As of Dec 24, the shareholder's funds were 424.15 million, and the total assets amounted to 884.58 million.

What does Abacus Life, Inc. do?

Abacus Life, Inc. is a blank check company in the insurance industry focused on business combinations, particularly in North America's energy sector. As of March 2025, it has a market cap of $536.49 million and reported a net profit of $5 million.

Overview:<BR>Abacus Life, Inc. is a blank check company in the insurance industry, focused on effecting business combinations, particularly in the energy sector in North America.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: 5 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 536.49 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -999,999.00<BR>Return on Equity: -2.95%<BR>Price to Book: 1.23<BR><BR>Contact Details:<BR>Address: 7777 Nw Beacon Square Blvd, BOCA RATON FL: 33487<BR>Tel: 1 561 8263620

Should I buy, sell or hold Abacus Life, Inc.?

Is Abacus Life, Inc. overvalued or undervalued?

As of August 12, 2024, Abacus Life, Inc. is considered overvalued and risky due to significant losses, a negative ROE of -2.95%, unfavorable key ratios compared to peers, and a year-to-date stock performance of -30.40% versus the S&P 500's 2.44% return.

As of 12 August 2024, the valuation grade for Abacus Life, Inc. has moved from very expensive to risky, indicating a shift in perception towards the company's financial health. The company is currently considered overvalued given its significant losses, reflected in a P/E ratio of NA and a negative ROE of -2.95%. Key ratios such as the Price to Book Value at 1.34 and an EV to EBITDA of 35.14 further underscore concerns regarding its valuation relative to its financial performance.<BR><BR>In comparison to peers, Abacus Life's valuation appears unfavorable; for instance, its peer has a P/E ratio of -41.77 and an EV to EBITDA of 33.24, suggesting that the market is pricing in significant risk for Abacus Life. Additionally, the company's stock has underperformed relative to the S&P 500, with a year-to-date return of -30.40% compared to the index's 2.44%. Overall, these factors contribute to the conclusion that Abacus Life, Inc. is overvalued in the current market environment.

Is Abacus Life, Inc. technically bullish or bearish?

As of October 24, 2025, Abacus Life, Inc. is in a bearish trend with weak strength, indicated by bearish daily moving averages and monthly MACD, while underperforming the S&P 500 with a year-to-date return of -25.29%.

As of 24 October 2025, the technical trend for Abacus Life, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the daily moving averages and the monthly MACD being bearish. The weekly MACD shows a mildly bullish signal, but this is overshadowed by the bearish signals from the monthly indicators and the overall trend change. Additionally, the company has underperformed significantly against the S&P 500 across multiple time frames, with a year-to-date return of -25.29% compared to the S&P 500's 15.47%.